Skip to main content

Table 3 Risks of hospitalized IS/SE and major bleeding among AF patients with non-diabetes, pre-diabetes, and diabetes

From: Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation

 

Event rate/100 person-years (95% CI)

Crude

Adjusted

HR (95% CI)

P value

HR (95% CI)a

P value

IS/SE

 Non-diabetes (HbA1c < 5.7%)

1.28 (1.18–1.38)

1.00 (Reference)

–

1.00 (Reference)

–

 Pre-diabetes (HbA1c 5.7–6.4%)

1.36 (1.27–1.44)

1.02 (0.92–1.13)

0.6968

1.02 (0.92–1.14)

0.6560

 Diabetes (HbA1c ≥ 6.5%)

1.52 (1.43–1.61)

1.26 (1.14–1.39)

< 0.0001

1.26 (1.13–1.41)

< 0.0001

 

Event rate/100 person–years (95% CI)

Crude

Adjusted

HR (95% CI)

P value

HR (95% CI)b

P value

Major bleeding

 Non-diabetes (HbA1c < 5.7%)

0.79 (0.71–0.87)

1.00 (Reference)

–

1.00 (Reference)

–

 Pre-diabetes (HbA1c 5.7–6.4%)

0.76 (0.70–0.83)

0.94 (0.82–1.07)

0.3298

0.94 (0.83–1.08)

0.3881

 Diabetes (HbA1c ≥ 6.5%)

0.82 (0.75–0.88)

1.11 (0.97–1.26)

0.1184

0.99 (0.86–1.15)

0.9122

  1. a Adjustments for CHA2DS2-VASc score, use of insulin or OHAs, use of warfarin or DOACs, and eGFR
  2. bAdjustments for HAS-BLED score, use of insulin or OHAs, use of warfarin or DOACs, and eGFR
  3. AF atrial fibrillation, CI confidence interval, DOACs direct oral anticoagulants, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin A1c, HR hazard ratio, IS/SE ischemic stroke or systemic embolism, OHAs oral hypoglycemic agents
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840